MVA 85A clinical trials

Studies by the year they started

25 studies that test it; most in 2003 (3)

Who runs them

Industry 0 · Other 25

University of Oxford (22) · Aeras (2) · Mark Hatherill (1)

Often tested with

Tested in the same studies.

BCG Vaccine (1)

Studies

Open first, then newest update. How each study uses MVA 85A is read from its arms, and is right about nine times in ten.

Testing it · 25

• EMaBS TB Vaccine StudyCompletedPhase 1/2University of OxfordNCT03681860Written as MVA85A
• MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) InfectionTerminatedPhase 1University of OxfordNCT02532036Written as Aerosol inhaled MVA85A
• A Study of MVA85A in Healthy InfantsCompletedPhase 2AerasNCT00953927Written as MVA85A/AERAS-485
• Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in HIV-Infected Adults (C-030-485)CompletedPhase 2AerasNCT01151189Written as MVA85A/AERAS-485
• Safety Study of ChAdOx1 85A Vaccination With and Without MVA85A Boost in Healthy AdultsCompletedPhase 1University of OxfordNCT01829490Written as MVA85A
• Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA85A, as a Way to Increase Immune Response and Avoid Anti-vector ImmunityCompletedPhase 1University of OxfordNCT01954563Written as MVA85A
• Safety and Immunogenicity of MVA85A Prime and Bacille Calmette-Guerin Boost VaccinationCompletedPhase 2Mark HatherillNCT01650389Written as MVA85A
• Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African AdolescentsCompletedPhase 2University of OxfordNCT02178748Written as MVA85A
• Phase I Trial Evaluating Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in BCG Vaccinated AdultsCompletedPhase 1University of OxfordNCT01879163Written as MVA85A-IMX313
• Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85ACompletedPhase 1University of OxfordNCT01683773Written as MVA85A
• A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85ACompletedPhase 1University of OxfordNCT01194180Written as MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu
• The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIVCompletedPhase 1University of OxfordNCT00395720Written as MVA85A (TB vaccine)
• A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or BothCompletedPhase 1University of OxfordNCT00480558Written as MVA 85A
• A Phase I Study of a New Tuberculosis (TB) Vaccine, MVA85A, in Healthy Volunteers With HIVCompletedPhase 1University of OxfordNCT00731471Written as MVA85A
• Safety of Tuberculosis Vaccine, MVA85A, Administered by the Intramuscular Route and the Intradermal RouteCompletedPhase 1University of OxfordNCT01181856Written as MVA 85A
• A Study of MVA85A in Healthy Children and InfantsCompletedPhase 2University of OxfordNCT00679159Written as MVA85A
• A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85ACompletedPhase 1University of OxfordNCT00653770Written as MVA85A
• Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI VaccinesCompletedPhase 1University of OxfordNCT00480454Written as MVA 85A
• Safety and Immunogenicity of MVA85A, in Healthy Volunteers in Cape TownCompletedPhase 1University of OxfordNCT00460590Written as MVA 85A
• A Study of 2 Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Previously Vaccinated With BCGCompletedPhase 1University of OxfordNCT00465465Written as MVA 85A

See all 25 studies that test MVA 85A →